Pluripotent Human Adipose Adult Stem Cells: Isolation, Characterization And Clinical Implications
Tech ID: 22650 / UC Case 2012-175-0
There are currently two main sources of PSCs. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSC). ESCs can be isolated from early stage embryos, though their use is fraught with ethical controversy. Reprogramming adult somatic cells to produce iPSC circumvents moral issues, but is still in its infancy. Unfortunately, both ECS and iPSCs exhibit an uncontrolled in vivo capacity for differentiation and proliferation, leading to the risk of unwanted teratoma formation in transplant recipients. Despite many efforts in the study of both PSCs, there has been little progress made in resolving the defects that stand in the way of their use in cell therapies for humans. Only two clinical trials have thus been implemented, one by Dr. Robert Lanza and his research team at the University of California, Los Angeles, and the other by the biopharmaceutical company, Geron, the latter of the two halting its clinical trial in 2011.
There is thus a need to identify a new population of human pluripotent stem cells; one that not only differentiates into other cell types, but also, one that does not produce potentially-malignant teratomas.
- Generation of patient-derived tissue for transplantation
- Source of cells at various developmental stages for research, including drug screening
- Treatment of neurological and immune disorders
- PASC isolation does not require the destruction of viable embryos.
- Formation of PASCs does not require extrinsically-induced differentiation genes, precluding unnecessary and potentially hazardous gene expression.
- PASCs can be isolated using a simple purification step without the need of further purification steps (e.g. cell sorting, magnetic beads, etc).
- PASC isolation require minimum cell manipulation.
- PASCs yield pluripotent stem cells after few days, in contrast to the weeks associated with generating ESC and iPSCs.
- PASCs do not form teratomas in animal models.
State Of Development
|Patent Cooperation Treaty||Published Application||WO2014190150||11/27/2014||2012-175|
Additional Patent Pending
- Chazenbalk, Gregorio
Stem cell, pluripotency, adipose tissue, regenerative, transplantation
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- A Novel Positron Emission Tomography Probe for Imaging Liver Disease and Metabolic Imbalance
- Diagnostic Tools for Response to 6-Thiopurine Therapy
- Diagnostic and Therapeutic Methods Using the H37 Tumor Suppressor Gene
- Pre-diagnostic And Therapeutics For Diabetes
- Proton-sensing G Protein-coupled Receptor 4 Knockout